
Medtronic (NYSE: MDT)
Medtronic Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Medtronic Company Info
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
News & Analysis
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever
These S&P 500 dividend stocks have fallen by up to 33% and are best buys now.
The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
A steady dose of quality companies will keep your portfolio growing big and strong.
1 No-Brainer Dividend Stock to Buy Now and Hold Forever
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Stock Instead?
5 Things You Need to Know If You Buy Medtronic Today
Valuation
Podcast Episodes
Will Wearable Technology Make Us Healthier?
Medtronic, Fitbit, Apple, and other tech companies hope to combine wearable technology with data analytics to improve outcomes in important diseases such as diabetes.
This Remarkable Device Revolutionizes Diabetes Treatment
The approval of Medtronic's artificial pancreas system ushers in a new era for type 1 diabetes treatment. Plus, a new study includes some surprising revelations regarding medical marijuana.
Earnings Transcripts
Medtronic (MDT) Q3 2025 Earnings Call Transcript
MDT earnings call for the period ending December 31, 2024.
Medtronic (MDT) Q2 2025 Earnings Call Transcript
MDT earnings call for the period ending September 30, 2024.
Medtronic (MDT) Q1 2025 Earnings Call Transcript
MDT earnings call for the period ending June 30, 2024.
Medtronic (MDT) Q4 2024 Earnings Call Transcript
MDT earnings call for the period ending March 31, 2024.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.